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Inhibition of resistance artery responses to endothelins (ETs) might
be useful in therapy-resistant hypertension and stroke. ETs cause long-
lasting arterial contractions by tight binding to smooth muscle ETA
receptors. Chemically diverse ET-receptor antagonists (ERA) inhibit
binding of ET-1 to ETA and reduce sensitivity to ETs. We investigated
negative allosteric modulation by ERA in isolated rat resistance arteries.
1 μM BQ123 (cyclic pentapeptide) reversibly relaxed contractile
responses to 32 nM ET-1 to a different extent in arteries from different
vascular beds (−0 to −80%) and reduced mesenteric artery (MA)
sensitivity to ET-1 more avidly (pKB 7.6 ±0.4) than that to ET-2 (pKB
5.6 ± 0.4). This agonist-dependence was less marked with 100 nM PD-
156707 (butenolide; pKB 8.5 ± 0.3 and 7.9 ± 0.3) and not signiﬁcant
with 1 nM BMS-193884 (biphenyl sulphonamide; pKB 9.3 ± 0.1 and
9.2 ± 0.1). Effects of high concentrations of BMS-193884 on MA
sensitivity to ET-1 and ET-2 were not concentration-dependent. In the
presence of 10 nMBMS-193884, i) 1 μMBQ123 had no additional effect
but ii) 100 nM PD-156707 resulted in a further signiﬁcant reduction of
MA sensitivity to ET-1. Binding i) a ﬂuorophore to PD-156707 (useful
for diagnosis) or ii) an angiotensin AT1-antagonistic moiety to BMS-
193884 (dual antagonist PS-433540) impaired ET-antagonism by the
pharmacophores. Thus, chemically distinct ERA act differently on
resting and agonist-activated ETA receptors and display system- and
agonist-dependence and saturability (pharmacological properties of
allosteric modulation). Also, the observations suggest the presence of
several allosteric binding sites on ETA receptors, the structure-activity
relationships of which can be studied.
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Extracellular superoxide dismutase (EC-SOD), one member of SOD
family, exists outside the cells in mammals. It catalyzes conversion of
superoxide anion (O2−) into hydrogen peroxide (H2O2), destroying
free radicals upon reactive oxygen species (ROS) production to relieve
oxidative stress. In this study, a methylotrophic Pichia pastoris system
was used to produce a large-scale of recombinant human EC-SOD by
yeast fermentation. After puriﬁed by fast protein liquid chromatogra-
phy (FPLC), three different subtypes of EC-SOD were performed.
Furthermore, the spontaneously hypertensive rat (SHR) was used to
examine anti-hypertension efﬁciency among different EC-SOD isoforms
through blood pressure measurement and NO release in blood after tail
intravenous injection of EC-SOD. Results showed that different subtypes
of EC-SOD share similar secondary structure but their activity diverse.
After injection of high-dose EC-SOD into SHR, we observed obvious
decrease of blood pressure and increase of blood nitric oxide (NO)
immediately. After blocking the NO synthesis, EC-SOD lost its ability of
blood pressure regulation. Our data provided that enormous antioxi-
dant and antihypertensive activities of human EC-SOD were largely
produced by yeast fermentation. It can be applied on the extent of
health care to prevent hypertension and also cardiovascular diseases.
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The fermented milk has antithrombotic, immunomodulatory,
antihypertensive and cardiovascular effects. In the present study,
the fermented milk and its derived peptide, 19AA, were investigated
for the ﬁrst time. Results demonstrated that the fermented milk had
a strong antihypertensive activity in spontaneous hypertension rats
(SHRs). Among two fractions derived from the fermented milk,
Fraction A exhibited the best antihypertensive activity. Following
reverse-phase high-performance liquid chromatography, a 19AA
short peptide was further puriﬁed and identiﬁed from Fraction A.
The synthetic peptide with a sequence of 19AA showed the strong
antihypertensive activity from 1 to 10 h after oral administration of
1 mg of 19AA/kg of body weight, and the effect of systolic and
diastolic blood pressure (SBP and DBP) decreasing was maximal at
44.0 ± 2.1 mmHg and 23.0 ± 2.9 mmHg, respectively, after oral
administration. The present study revealed that 19AA showed
excellent antihypertensive activity, and its activity is better than
that of VPP tripeptide which has been already included in functional
foods. In conclusion, the 19AA fermented peptide is the bioactive
ingredient with potential beneﬁt in the prevention and treatment of
hypertension or other associated disorders.
doi:10.1016/j.lfs.2013.12.150
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Background: ET-1 levels rise in PAH, correlating with increased
pulmonary vascular resistance and mortality. Lung endothelial ETB
receptors promote ET-1 clearance, which is improved in PAH
patients by epoprostenol (prostacyclin). Whether prostacyclin
analogues behaviour similarly is unclear or if smooth muscle ETB
receptors regulate ET-1 levels. Methods: Cultured human PASMCs
from PAH patients were treated for 24 h with treprostinil, an ETRA or
a combination. A chemiluminescent ELISA was used to measure ET-1
in the supernatant while ET-1 converting enzyme (ECE-1) and ETB
expression were evaluated by Westerns and immunohistochemistry
in lung sections. Results: Serum doubled ET-1 levels in HPSMCs, an
effect abolished by treprostinil (10–100 nM). In contrast, the ERTAs
(100 nM) bosentan and ambrisentan increased ET-1 levels by 100%
while BQ788 (selective ETB antagonist) by 200%. Treprostinil in
combination with these ETRAs failed to inhibit serum-induced ET-1
elevation. In contrast, BQ123 (selective ETA antagonist) did not affect
the response to serum or treprostinil. ECE-1 protein levels were
higher with BQ788 and bosentan compared to serum or treprostinil.
Furthermore, ETB expression was down-regulated by all ETRAs, but
not by treprostinil. In the smooth muscle layer of PAH lungs,
ECE-1 and ETB expression was markedly increased. Conclusion:
Treprostinil potently inhibits ET-1 levels in human PASMCs which
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